Actinium Pharmaceuticals Inc (ATNM) Quote

Good luck. Something’s gotta give soon! I’d love to see that 25 dollar mark before the end of the year.

Back in with the first buy in a long time... Still have a target price of $25.. Ticked that CRMD has taken so long to get going cause it made me miss one heck of a buying opp on ATNM sub $5...

Now to start selling covered calls and see if I can keep the shares..


Good luck..

The troll idiot rides again making up lies when his ass gets burned.

LMAO, what a piece of work.

LOL!! Is this your "timing" post?? Yes, you only made it 8 years ago....great timing....of course the stock was around $62 then

Monroe1

Re: None

Tuesday, September 27, 2016 10:17:02 AM

Post#
1092
of 2790
So what is the ETA for lomab coming out of phase3 and approval?
Mid 2017 or earlier perhaps??

Suppose that PT is raised in light of AZN buying Fusion at ~ 100% premium today? Much needed Actinium involved there also

Maxim Group Maintains Buy on Actinium
Pharma, Raises Price Target to $30
3/19/2024 12:59pm
12:59 PM EDT, March 19, 2024 (Benzinga Newswire)
Maxim Group analyst Jason McCarthy maintains
Actinium Pharma (AMEX:ATNM) with a Buy and raises the price target from $20 to $30.
Write to Benzinga at editorial@benzinga.com

I continue to believe that potential suitors are waiting for ATNM to, at the very least, submit their application to the FDA. Possibly the company even had some offers but would be in a better position to negotiate after approval?

Watching Actinium Pharmaceuticals; HC
Wainwright: First Take Says 'Appetite Remains High For Radiopharmaceuticals;
We See Actinium As Ripe For Takeout And Believes It Is Receiving M&A Interest'
3/19/2024 11:24am

HC Wainwright & Co. Maintains Buy on Actinium Pharma, Maintains $50 Price Target
3/19/2024 11:19am
11:19 AM EDT, March 19, 2024 (Benzinga Newswire)
HC Wainwright & Co. analyst Joseph Pantginis maintains Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price target.
Write to Benzinga at editorial@benzinga.com

Good news but we can sure use that FDA submission.

Actinium Pharmaceuticals Disclosed The Launch Of Strategic Initiative Focused On The Manufacture Of The Highly Sought After Medical Isotope Actinium-225 (Ac-225)
3/14/2024 6:11am

News 3-11-2024
https://www.otcmarkets.com/stock/ATNM/news/story?e&id=2791660

Yes, but I also think many thought that the company was setting up for a pr letting us know they finally applied for FDA approval. I still think they will- but probably later this year.

Perhaps it is the result of a delayed market reaction to the ATNM PR dated 2/28/2024.

There were a couple of articles/abstracts that were recently published that were positive for one of the companies products ( I believe it was Iomab?). I think the presumption was that the company was soon going to submit for FDA approval for that product. No word as of yet to that end.

Anyone know why we have moved from $4 to the high of $8.78?
I should have bought more at $4 but I don’t think we are going to see that again.

How to calculate the value of drugs and biotech companies

https://www.baybridgebio.com/drug_valuation.html

current target price is $27 based on the one product they are going to apply for approval of.

To see $100, all of those other ones in development/trials are going to have to 'show' something during their PH 2s..

Disclaimer: nice frigging move off the $4/sh lows... Been wondering WHAT someone knows and I suspect its got to do with
the pending NDA submission which is expected to take place sometime before the 3rd qtr..
Don't own any because I am still fully committed to another one about to commence its sales post its FDA approval...
And its something that should have happened at least 2 years earlier but thats been delayed and ruined my plans of rotating some
out of that one into ATNM..

The Reddit short squeeze crowd will pounce on this stock as soon as the April 2024 $15 stock warrants that ATNM has on its books expire in about eight weeks. The warrants are used by short selling institutions as protection against infinite loss in the event of a buyout. Without this protection against infinite losses the short selling institutions will go away and maybe go long. There are a little over 1.2 million warrants on the books today, all set to expire very soon. Then the path of least resistance is up, could trade in the $100s very fast. I've been buying since the drop last year. I'm not trading I'll just wait on the buyout.

agree with you... What was the purpose for the question when it would be very easy to look thru their PR to see if one had been
issued.

But again, ya can't get one till an NDA review has commenced as far as I am aware of.

But on a side note, nice move developing in the share price and have to wonder if its in anticipation of the NDA submission pending..

disclaimer: hadn't bought any back yet because of a delay in things moving forward in CRMD (has been approved, expected to commence sales in April, but the market has not run it up as expected in anticipation of this occurring as it would normally be expected to happen: share price $3.33, 1st target price is $14-15 and I own shares. So yeah, its slow move has cost me a chance to flip some of those shares for ATNM which I had fully intended to do.. Dang nab it all)

To my knowledge ATNM har never received a CRL letter. They haven't filed BLA either, so I don't see why you ask this question.

what was the date of atnm's crl letter?

Nice to see these Pharmaceuticals go up today!
ATNM up 2.95%
ATNM had 200 shares trade in after hours $5.23
JAGX hit .1362 in after hours
TCON hit .2304 in after hours

All these need to get back over the 52 week high.

The company will file a BLA for Iomab B the first half of this year. And I think we'll sign a deal for Asia marketing rights in the same time frame. This company will be bought out imo.

I haven’t seen any recent updates. Does anyone know the latest on approvals or submittals

a lot of 'baby' bios are getting hacked up. CRMD for example just rec'd FDA approval of a compound that WILL become the standard of care because of its effectiveness. And despite the news, since the 'launch' isn't till (later?) in the 1st qtr 2024, its gone 'no where' on the news.

ATNM has gotten clocked, but what the heck, given a target price of $20+ (if they would stop selling frigging shares), its a 'gift' at these prices. But like CRMD, its going to have to EXECUTE (get approved and get sales going).

Got 1 other that has very good potential, but again, folks just don't seem to be interested in something that isn't 'doing'

I was just browsing thru their website, going over their Nov presentation. Was looking for an update on the BLA filing, see someone posted its now into the 1H 2024. Was going to start accumulating, but a look at the chart is indicating $4 may not hold now. So going to continue to be patient. Cause I suspect given the early stages for the rest of their effort (and years to an endpoint), the only thing that might turn this around would be news of the filing. And with that pushed back? LIke CRMD, the market is not being kind to baby bios. Course the other thing is, when the market turns from 'no price is too high' to lets get 'real''? Whats a 'fair value' takes on a whole different perspective. (example: Sava back when it was completing a PH 2 hit over $120/sh look at where its at now..and I would argue its still overvalued given what they have PROVEN)

Disclaimer: still being patient to buy back in.. And getting it down here just increases the potential reward if they can get approved)

Are you looking at another chart than me? On the six month chart the SP has been cut in half. The last pull was BLA filing being moved from H2 23 to H1 24.

Any updates here?? Seems to keep moving sideways.

Actinium Pharmaceuticals announced that it will be attending Bio-Europe, the
largest biopharmaceutical industry partnering event in Europe, taking place November 6 -- 8, 2023 in Munich, Germany.

Members of Actinium's senior leadership team will be available for one-on-one meetings during the in-person meeting as
well as the digital partnering taking place November 14-15, 2023. To request a meeting with Actinium through
partneringONE(R) https://informaconnect.com/bioeurope/. Interested parties may also contact the Company directly to
schedule in person or virtual meetings by emailing Actinium.

Actinium is advancing a pipeline of differentiated, clinical-stage targeted radiotherapeutics including Iomab-B for
bone marrow transplant conditioning, which met the primary endpoint in the Phase 3 SIERRA trial and is being prepared
for a BLA filing, Iomab-ACT for conditioning prior to cell and gene therapy and Actimab-A as a therapeutic for relapsed
or refractory acute myeloid leukemia that has shown backbone therapy potential in combinations. Actinium is also
advancing novel solid tumor programs leveraging its industry leading experience with the alpha-particle payload
Actinium-225 and intellectual property including linker technology and Actinium-225 manufacturing.

Don’t get me wrong. I still have faith in the science and want to believe the company will come through with the ultimate goal of submission and approval. These down days are difficult to take after an already long process. If I had some dry powder, I’d probably see it as an opportunity as well. Maybe I’m hoping for a glimmer of positivity that would help support the share price in the near term? Thanks for the encouraging example though.

But the opportunity to be taken advantage of.

Had another one CRMD get I suspect 'shorted' down heavily in the run up to its pending decision date (Nov 15th. Now at $3.3-3.4 range, target is still $14-15)..

Been watching ATNM and kind of wondering if it would get a similar share price hit.

And as far as I know, its still on track for an NDA submission before the end of the year?? So going to take advantage of this and start accumulating a position. And see it still has a target price of $27 making this price level or less, one heck of a buy given that their development 'appears/sounds' successful/approvable.

Disclaimer: own none at the moment, but going to after this takedown.

Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
November 02 2023 - 09:05AM
PR Newswire (US)
Alert
Print
Share On Facebook
- Relapsed or refractory AML patients with a TP53 mutation receiving Iomab-B led allogeneic bone marrow transplant had a median Overall Survival of 5.49 months compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002)

- Iomab-B's mutation-agnostic mechanism overcomes TP53 mutations and produced similar median Overall Survival outcomes of 6.37 months in TP53 negative patients and 5.72 months in TP53 positive patients

- Twenty-four percent of patients enrolled on SIERRA had a TP53 mutation that is typically associated with worse outcomes

- Oral presentation scheduled for Sunday, December 10, 2023, with two additional poster presentations detailing SIERRA trial results accepted for presentation

- Actinium reports third quarter financial results and provides a business update

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that three abstracts detailing results from the completed Phase 3 SIERRA trial of Iomab-B in patients age 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML) have been accepted for presentation at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH) being held in San Diego on December 9-12, 2023. Outcomes of patients with a TP53 gene mutation enrolled in the SIERRA trial have been accepted for an oral presentation and results detailed in the abstract include the following:

(PRNewsfoto/Actinium Pharmaceuticals, Inc.)

Median Overall Survival (OS) of TP53 positive patients receiving Iomab-B and a bone marrow transplant (BMT) was 5.49 months compared to 1.66 months in patients who did not receive Iomab-B
Iomab-B produced a statistically significant improvement in median OS in TP53 positive patients with a hazard ratio of 0.23 and p-value of 0.0002
Median OS of 6.37 months in TP53 negative patients receiving Iomab-B and 5.72 months for TP53 positive patients demonstrating Iomab-B's mutation agnostic mechanism and ability to overcome TP53 gene mutations
24% of patients (37/153) enrolled on the SIERRA trial had a TP53 mutation, with 17 being randomized to the Iomab-B arm and 20 randomized to the control arm
Dr. Avinash Desai, Actinium's Chief Medical Officer, commented, "We are very excited by these results which show a statistically significant and greater than three-times increase in median OS in TP53 positive patients receiving Iomab-B. These results further support Iomab-B's differentiated profile and ability to improve outcomes for the most difficult to treat r/r AML patients. A TP53 gene mutation is arguably the most unfavorable risk factor leading to the worst patient outcomes as it is associated with inherent resistance to available therapies, short duration of responses and the lowest survival rates. Despite being a common mutation found in approximately 10-15% of all AML cases and up to 25% of patients over age 60, there are no approved therapies that target TP53. For patients with high-risk AML, particularly those with r/r disease and a TP53 mutation, BMT is associated with the best treatment outcomes and is the only potentially curative therapeutic option. Iomab-B's ability to facilitate a BMT in this patient population continues to demonstrate a strong clinical benefit as supported by these results and we look forward to presenting the full TP53 analysis at ASH in early December."

Detailed results will be presented in an oral presentation on December 10, 2023, as follows:

Session Name: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Novel Conditioning Regimens for Myeloid Malignancies
Session Date: Sunday, December 10, 2023
Session Time: 9:30 AM - 11:00 AM Pacific Time
Presentation Time: 9:30 AM
Room: Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

Publication Number: 469
Title: 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML
Submission ID: 182177

Iomab-B is a new type of treatment for patients with relapsed or refractory acute myeloid leukemia (r/r AML), a type of blood cancer that is difficult to treat and has a poor prognosis.

Iomab-B is a targeted radiotherapy that uses a monoclonal antibody to deliver radiation directly to the bone marrow and spleen, where most of the leukemia cells are located.

This way, Iomab-B can destroy the cancer cells and prepare the patient for a bone marrow transplant (BMT), which is a potentially curative procedure.

Iomab-B has been tested in a large clinical trial called SIERRA, which showed positive results for patients who received Iomab-B and BMT compared to those who received conventional chemotherapy and BMT.

Some of the key findings from the SIERRA trial are:
• All patients who received Iomab-B were able to access BMT, while only 17% of patients who received chemotherapy were able to do so1.
• Patients who received Iomab-B had a higher rate of remission after BMT than those who received chemotherapy (75% vs 6.3%)1.
• Patients who received Iomab-B had a longer median overall survival than those who received chemotherapy (6.37 months vs 1.66 months)2.
• Patients who had a TP53 gene mutation, which is associated with worse outcomes in AML, had a similar median overall survival as those who did not have the mutation when they received Iomab-B (5.72 months vs 6.37 months)2.
• Iomab-B was well tolerated and had manageable side effects1.
Iomab-B is a promising new therapy for r/r AML patients who need a BMT but cannot achieve remission with conventional chemotherapy.

It is currently under review by the FDA for approval3.

If you want to learn more about Iomab-B, you can visit the official website of the SIERRA trial4 or the website of Actinium Pharmaceuticals, the company that developed Iomab-B1.

Ouch

Part of me agrees that the FDA is already in the big pharma’s back pocket. A greater part of me thinks in ATNM’s case at least, the delay may be more due to 1. The limited resources the company has to provide a viable NDA. 2. The impact of ATNM’s treatment vs. say the COVID vaccine in terms of patients served.

I am starting to wonder if the 'length' of time to get something approved is relational to whether its a 'baby bio' vs one of the big pharma - fda 'revolving' door companies up for approval.

And yeah, the covid scam/hoax demonstrated how things 'really' work when 'something' is 'desired' didn't it.

Great things are ahead indeed

Wow, great information! Thanks for sharing.

Found this on stocktwits
https://stocktwits.com/resume777/message/544196854
For those wondering what’s going on behind the scenes. Iomab-B, $ATNM lead PHIII complete cancer treatment, is being presented to the Department of Health & Human Services Centers for Medicare & Medicaid Services on September 12, 2023 for the determination of Iomab-B ICD-10 codes. Used for medical claim reporting in all healthcare settings, ICD-10 codes are the primary means to establish medical necessity for payment of healthcare services and procedures.
April 2024 implementation.
It doesn’t look like they are covering these NTAPS on the zoom
https://www.cms.gov/medicare/coding/icd10/c-and-m-meeting-materials/2023-09-12-icd10-meeting-materials
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 CENTER FOR MEDICARE ICD-10 Coordination and Maintenance Committee Meeting ICD-10-PCS Therapeutic Agent Topics Consistent with the requirements of section 1886(d)(5)(K)(iii) of the Social Security Act, applicants submitted requests to create a unique procedure code to describe the administration of a therapeutic agent, such as the option to create a new code in Section X within the International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS). CMS is soliciting public comments on the proposed coding options and any clinical questions for two procedure code topics associated with new technology add-on payment (NTAP)-related ICD-10- PCS procedure code requests that involve the administration of a therapeutic agent. The deadline to submit comments for these topics being considered for an April 1, 2024 implementation is October 13, 2023. Members of the public should send any questions or comments to the CMS mailbox at: ICDProcedureCodeRequest@cms.hhs.gov. Prior to the meeting, CMS will post a question and answer document on our website at https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials to address clinical or coding questions that members of the public have submitted related to the two therapeutic agents, as discussed in the following pages. At a later date, CMS will post an updated question and answer document to address any additional clinical or coding questions that members of the public may have submitted by the October 13, 2023 deadline. CMS will not be presenting the NTAP-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent at the September 12, 2023 virtual meeting. CMS will present the NTAP-related ICD-10-PCS procedure code requests that do not involve the administration of a therapeutic agent and all non-NTAP-related procedure code requests during the virtual meeting on September 12, 2023. Comments on all procedure code proposals should be sent to the following email address: ICDProcedureCodeRequest@cms.hhs.gov.

Looking for info on the above I got this from ai chat
I’m sorry, but I couldn’t find any specific information about the presentation of Iomab-B’s Phase III complete cancer treatment to the Department of Health & Human Services Centers for Medicare & Medicaid Services on September 12, 2023, for the determination of Iomab-B ICD-10 codes. However, I can share that Iomab-B is a first-in-class targeted radiotherapy developed by Actinium Pharmaceuticals1. It has shown positive results in the pivotal Phase 3 SIERRA Trial for patients with active relapsed or refractory Acute Myeloid Leukemia32. The trial met its primary endpoint of durable complete remission of 6-months following initial complete remission after Hematopoietic Cell Transplantation (HCT) with a p-value of

Good news premarket trade $7.68

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172761069&txt2find=atnm

My bet is they do but my time horizon is longer if they don’t make year’s end.

So will we see BLA before the end of the year?

So many of these biotechs are taking “far longer than expected”. I’ve been waiting on NWBO forever (and still believe I will eventually come out with at least a 10 bagger upon approval). I hope your Cormedix bears fruit soon but I’m quickly finding out that unless you have the metaphorical “cure for COVID”, nothing happens quickly in the world of biotech!

agree. Just that I am 'all in' on CRMD and its pending Nov 15th date with the FDA.. Looking for $12 to $15 on that one for starters. Damn delays in its approval have cost me 'opportunities' on another one as I have had to 'wait'... far longer than expected over 2 years ago.. And now a bargain on ATNM

Be nice to roll some of that one into some shares sub $8 on this one..

Just bought a little more to add to my small position as this is too tempting an opportunity.

Been a while, but have been monitoring the share price trend. Also tracking the FLOAT, hope they can keep it sub 30 Mil shares (26 Mil) so that the darn 'target price' doesn't get hit like it has for one I am heavily in at the moment (delays in their approval timeline has forced ATM dilution).
And know this won't be a likeable comment, but if it can hold sub $8 into the end of the year?? With a target price of around $25-30?? Be a happy buyer for the run into their approval decision (question is, are they still on track for an NDA submission late this year??)

disclaimer: currently own none, but am bullish especially as the price has slid lower

Would be nice for another update soon

@4 follow for you , PLEASE hit me back